Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study (P01.165)

CONCLUSIONS: The long-term safety results of FREEDOMS II extension study were generally consistent with previous fingolimod studies. Switching therapy from placebo to fingolimod after 24 months identified no unexpected safety concerns.Supported by: Novartis Pharma AG, Basel, Switzerland.Disclosure: Dr. Vollmer has received personal compensation for activities with Genzyme Corporation, Acorda Therapeutics, Accelerated Cure Projects for MS, Bristol-Myers Squibb Company, Teva Neuroscience, Biogen Idec, Novartis, and Hoffman-LaRoche. Dr. Vollmer has received research support from Teva Neuroscience, Genzyme Corporation, Ono Pharmaceutical, Biogen Idec, Janssen, and the National Institutes of Health. Dr. Jeffery has received personal compensation for activities with Berlex Laboratories, Inc., GlaxoSmithKline, Inc., Pfizer Inc, Serono, Inc., and Teva Neuroscience. Dr. Jeffrey has received research support from Berlex, Pfizer Inc, Serono, Inc., and Teva Neuroscience. Dr. Goodin has received personal compensation for activities with Ares-Serono, Merck Serono, Novartis, Berlex Laboratories, Bayer Schering HealthCare, Biogen Idec, Schering AG and Teva Neuroscience. Dr. Goodin has received research support from Novartis. Dr. Kappos has receied personal compensation for activities with Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, Genmark, GeNeuro SA and GlaxoSmithKline. Dr. Ka...

Source: Neurology - February 14, 2013 Category: Neurology Authors: Vollmer, T., Jeffery, D., Goodin, D., Kappos, L., Lublin, F., Radue, E.-W., Rammohan, K., Reder, A., Agius, M., Stites, T., Li, B., Cappiello, L., von Rosenstiel, P., Calabresi, P. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research